Get started

Financials · INMB

INmune Bio Inc. (INMB) financials

For fiscal 2025 (ended Dec 31, 2025), INmune Bio Inc. reported $50.0K of revenue and -$45.93M of net income.

Revenue, FY2025
$50.0K
Revenue growth, YoY
+257.1%
Net income, FY2025
-$45.93M
Net margin
-91866.0%
Free cash flow, FY2025
-$23.62M
EPS, diluted, FY2025
-$1.86
Cash
$16.33M
P/S
699.68
Market cap
$35.0M
Annual revenue$50.0K
FY2017FY2025
Annual net income-$45.93M
FY2017FY2025

INMB revenue and earnings growth

INMB revenueQ4 2025$0

FY YoY
+257.1%
5Y CAGR
+35.4%

INMB revenue was $0 in fiscal Q4 2025 (ended Dec 31, 2025), compared with $0 a year earlier. For the full fiscal 2025 it was $50.0K, up 257.1% from fiscal 2024. Compound annual growth was +35.4% over 5 years. It rose in 3 of the last 5 fiscal years.

INMB net incomeQ3 2026-$4.72M

INMB net income was -$4.72M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$6.47M a year earlier. For the full fiscal 2025 it was -$45.93M, compared with -$42.08M in fiscal 2024.

INMB EPSQ3 2026-$0.17

INMB diluted EPS was -$0.17 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.24 a year earlier. For the full fiscal 2025 it was -$1.86, compared with -$2.11 in fiscal 2024.

INMB free cash flowQ4 2025-$3.09M

INMB free cash flow was -$3.09M in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was -$23.62M.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue$50.0K$14.0K$155.0K$374.0K$181.0K$11.0K-$0$0
Research and development$20.66M$33.17M$20.27M$17.07M$20.54M$5.92M$3.28M$3.35M$435.4K
Selling, general and admin$10.26M$9.48M$9.62M$9.26M$8.79M$6.32M$6.02M$9.09M$546.1K
Operating income-$47.38M-$42.63M-$29.74M-$25.95M-$29.15M-$12.23M-$7.76M-$12.44M-$981.5K
Interest expense-$789.0K$2.28M$2.01M-----
Pre-tax income$45.93M$42.08M$30.01M------
Income tax-------$0$0
Net income-$45.93M-$42.08M-$30.01M-$27.30M-$30.34M-$12.10M-$7.68M-$12.44M-$831.5K
EPS, basic-$1.86-$2.11-$1.67-$1.52-$1.88-$1.01-$0.75-$1.43-$0.13
EPS, diluted-$1.86-$2.11-$1.67-$1.52-$1.88-$1.01-$0.75-$1.43-$0.13
Diluted shares24.8M19.9M18.0M17.9M16.1M12.0M10.3M8.7M6.6M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Cash and equivalents$24.75M$20.92M$35.85M$52.15M$74.81M$21.97M$7.00M$186.2K$1.37M
Receivables$4.28M$1.18M$1.91M------
Current assets$29.89M$22.66M$39.94M$64.67M$82.61M$23.99M$7.76M$849.3K$1.90M
Total assets$32.35M$39.56M$57.00M$81.80M$99.94M$40.66M$24.47M$17.36M$18.41M
Current liabilities$8.42M$7.22M$18.46M$10.92M$4.36M$1.78M$700.4K$823.8K-
Short-term debt--$9.92M$5.00M-----
Long-term debt---$9.70M-----
Total debt-$15.00M-$14.70M$15.00M----
Total liabilities$8.83M$7.46M$18.86M$21.69M$19.72M$1.90M$860.5K$823.8K$309.7K
Shareholders' equity$23.52M$32.10M$37.34M$60.10M$80.22M$38.75M$23.61M$16.54M$18.10M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Operating cash flow-$22.58M-$33.36M-$11.98M-$22.69M-$28.50M-$8.94M-$5.38M-$2.06M-$761.8K
Capital expenditures$1.04M--------
Free cash flow-$23.62M--------
Investing cash flow-$1.04M----$15.00M----$100.0K
Financing cash flow$27.61M$18.21M-$4.22M$729.0K$96.36M$23.89M$12.21M$900.0K$2.06M
Stock-based compensation$9.91M$7.61M$7.37M$7.15M$4.80M$3.11M$4.10M$10.00M$199.6K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
Revenue growth, YoY257.1%-91.0%-58.6%106.6%1545.5%----
Operating margin-94766.0%-304535.7%-19187.7%-6938.8%-16106.6%-111163.6%---
Net margin-91866.0%-300585.7%-19360.0%-7299.2%-16762.4%-109990.9%---
Free cash flow margin-47248.0%--------
Return on equity-195.3%-131.1%-80.4%-45.4%-37.8%-31.2%-32.5%-75.2%-4.6%
Return on assets-142.0%-106.4%-52.6%-33.4%-30.4%-29.8%-31.4%-71.6%-4.5%
Current ratio3.553.142.165.9218.9513.5111.091.03-
Debt to equity-0.47-0.240.19----

Source: XBRL data INmune Bio Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

INMB peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
INMB$50.0K+257.1%-$45.93M-91866.0%$35.0M
IBRX$165.79M+192.9%-$992.37M-598.6%$9.15B
PALI$500.0K--$31.94M-6388.2%$196.9M
GOSS$53.29M+32.4%-$125.22M-235.0%$59.8M
TIL$8.97M+2.5%-$30.28M-337.7%$46.3M

INMB FAQ

8 questions
  • What is INMB revenue?
    INmune Bio Inc. (INMB) reported $50.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 257.1% from the year before.
  • Is INMB profitable?
    No. INmune Bio Inc. reported a net loss of $45.93M for fiscal 2025 (ended Dec 31, 2025).
  • How much cash and debt does INMB have?
    INmune Bio Inc. reported $16.33M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is INMB revenue growing?
    INmune Bio Inc.'s revenue changed +257.1% in fiscal 2025, to $50.0K. Its compound annual growth rate was +35.4% over 5 years.
  • What is INMB free cash flow?
    INmune Bio Inc. generated -$23.62M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$22.58M less capital expenditures.
  • What is INMB earnings per share?
    Diluted earnings per share were -$1.86 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.
  • When did INMB last report financial results?
    The latest statements here come from INmune Bio Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this INMB financial data come from?
    Quantisnow builds these statements from the structured XBRL data INmune Bio Inc. files with the SEC. It is provided for information only and is not investment advice.